Nordic collaboration through JNHB

Nordic collaboration through JNHB

Joint Nordic HTA-bodies (JNHB) is a project launched by Nordic authorities responsible for HTA assessments with the aim of increasing and developing collaboration in HTA assessments and accelerating the availability of new medicines to patients. The members include the Finnish Medicines Agency (Fimea), the Swedish Dental and Pharmaceutical Benefits Agency (TLV), the Norwegian Medicines Products Agency (NOMA), the Danish Medicines Council (DMC) and the National University Hospital of Iceland (Landspitali ). The collaboration includes both joint assessment of relative effectiveness and applicable parts of economic evaluation. The collaboration was launched in 2017 under the name FINOSE at the initiative of Fimea, NOMA and TLV. Denmark and Iceland joined in 2023 and 2024, respectively.

From the perspective of a participating company, the collaboration means that the assessment is launched simultaneously in all Nordic countries. Collaboration requires consent from the company to share confidential information between agencies. Decisions on the use of a medicinal substance based on the collaborative assessment are made separately in each country in accordance with national regulations. 

If your company is interested in the joint Nordic assessment, please contact either a participating agency directly or JNHB's shared email address [email protected]. More information on JNHB collaboration and materials such as the joint assessment process description are available on the JNHB website at https://jnhtabodies.org/.

FINOSE sininen boksi

Ask more

 [email protected]

Tuomas Oravilahti, pharmacoeconomist, tel. +358 20 522 3521

Vesa Kiviniemi, Head of Assessment, tel. +358 29 522 3516

Email address format: [email protected]